Moderna expects to report vaccine data for young children in March
If the data are supportive and, subject to regulatory consultation, Moderna may proceed with regulatory filings
If the data are supportive and, subject to regulatory consultation, Moderna may proceed with regulatory filings
Moderna Inc. on Wednesday said it expects to report data from its Covid-19 vaccine trial in children ages 2 to 5 in March.